首页> 外文OA文献 >The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279

【2h】

The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279

机译：使用抗VEGF的安全性：是否有强度？ Curtis LH，Hammill BG，Schulman KA，Cousins SW（2010）与年龄相关性黄斑变性治疗相关的死亡，心肌梗塞，出血和中风的风险。弓眼药水128（10）：1273-1279

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
David Wong; Antonia M. Joussen;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279. [J] . Wong D, Joussen AM Graefe's archive for clinical and experimental ophthalmology: Albrecht von Graefes Archiv fur klinische und experimentelle Opthalmologie . 2011 ,第2期

机译：使用抗VEGF的安全性：是否有强度？ Curtis LH，Hammill BG，Schulman KA，Cousins SW（2010）与年龄相关性黄斑变性相关的死亡，心肌梗塞，出血和中风的风险。拱眼药水128（10）：1273-1279。
2. The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279 [J] . David Wong, Antonia M. Joussen Graefe's Archive for Clinical and Experimental Ophthalmology . 2011 ,第2期

机译：使用抗VEGF的安全性：是否有强度？ Curtis LH，Hammill BG，Schulman KA，Cousins SW（2010）与年龄相关性黄斑变性的治疗相关的死亡，心肌梗塞，出血和中风的风险。弓眼药水128（10）：1273-1279
3. The safety of using anti-VEGF: Is there strength in numbers? Curtis LH Hammill BG Schulman KA Cousins SW (2010) Risks of mortality myocardial infarction bleeding and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279 [O] . David Wong, Antonia M. Joussen -1

机译：使用抗VEGF的安全性：是否有强度？ Curtis LHHammill BGSchulman KACousins SW（2010）与年龄相关性黄斑变性的治疗相关的死亡心肌梗塞出血和中风的风险。弓眼药水128（10）：1273-1279
4. The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279 [O] . Wong, David, Joussen, Antonia M. 2011

机译：使用抗VEGF的安全性：是否有强度？ Curtis LH，Hammill BG，Schulman KA，Cousins SW（2010）与年龄相关性黄斑变性治疗相关的死亡，心肌梗塞，出血和中风的风险。弓眼药水128（10）：1273-1279

The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279

著录项

相似文献

相关主题

期刊订阅